
Sign up to save your podcasts
Or


Hartmut Ehrlich, CEO of Abivax, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Abivax is working to develop treatments modulating the body’s natural immune system to treat patients with chronic inflammatory diseases, viral infections and cancer.
By John Simboli5
77 ratings
Hartmut Ehrlich, CEO of Abivax, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Abivax is working to develop treatments modulating the body’s natural immune system to treat patients with chronic inflammatory diseases, viral infections and cancer.

3,072 Listeners

1,993 Listeners

1,105 Listeners

2,342 Listeners

943 Listeners

797 Listeners

125 Listeners

337 Listeners

6,097 Listeners

95 Listeners

10,254 Listeners

551 Listeners

152 Listeners

248 Listeners

187 Listeners